Normal view MARC view ISBD view

Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer (Record no. 19128)

MARC details
000 -LEADER
fixed length control field	04906nam a22008537a 4500
003 - CONTROL NUMBER IDENTIFIER
control field	OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field	20240305193716.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field	221010b \|\|\|\|\|\|\|\| \|\|\|\| 00\| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number	Online ISSN 1557-3265

International Standard Serial Number	Print ISSN 1078-0432
028 ## - PUBLISHER OR DISTRIBUTOR NUMBER
Source	Phone: +255 28 298 3384

Source	Fax: +255 28 298 3386

Source	Email: vc@bugando.ac.tz
035 ## - SYSTEM CONTROL NUMBER
System control number	Website: www.bugando.ac.tz
040 ## - CATALOGING SOURCE
Transcribing agency	DLC
041 ## - LANGUAGE CODE
Language code of text/sound track or separate title	English
245 ## - TITLE STATEMENT
Title	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc.	Mwanza, Tanzania:
Name of publisher, distributor, etc.	American Association for Cancer Research &
--	Catholic University of Health and Allied Sciences [CUHAS – Bugando]
Date of publication, distribution, etc.	2018/2/1
300 ## - PHYSICAL DESCRIPTION
Extent	Pages 569-580
490 ## - SERIES STATEMENT
Volume/sequential designation	Clinical Cancer Research Volume 24 Issue 3
520 ## - SUMMARY, ETC.
Summary, etc.	Abstract<br/><br/>Purpose: Women with epithelial ovarian cancer generally have a poor prognosis; however, a subset of patients has an unexpected dramatic and durable response to treatment. We sought to identify clinical, pathological, and molecular determinants of exceptional survival in women with high-grade serous cancer (HGSC), a disease associated with the majority of ovarian cancer deaths.<br/><br/>Experimental Design: We evaluated the histories of 2,283 ovarian cancer patients and, after applying stringent clinical and pathological selection criteria, identified 96 with HGSC that represented significant outliers in terms of treatment response and overall survival. Patient samples were characterized immunohistochemically and by genome sequencing.<br/><br/>Results: Different patterns of clinical response were seen: long progression-free survival (Long-PFS), multiple objective responses to chemotherapy (Multiple Responder), and/or greater than 10-year overall survival (Long-Term Survivors). Pathogenic germline and somatic mutations in genes involved in homologous recombination (HR) repair were enriched in all three groups relative to a population-based series. However, 29% of 10-year survivors lacked an identifiable HR pathway alteration, and tumors from these patients had increased Ki-67 staining. CD8+ tumor-infiltrating lymphocytes were more commonly present in Long-Term Survivors. RB1 loss was associated with long progression-free and overall survival. HR deficiency and RB1 loss were correlated, and co-occurrence was significantly associated with prolonged survival.<br/><br/>Conclusions: There was diversity in the clinical trajectory of exceptional survivors associated with multiple molecular determinants of exceptional outcome in HGSC patients. Concurrent HR deficiency and RB1 loss were associated with favorable outcomes, suggesting that co-occurrence of specific mutations might mediate durable responses in such patients. Clin Cancer Res; 24(3); 569–80. ©2017 AACR.
700 ## - ADDED ENTRY--PERSONAL NAME
9 (RLIN)	44533

9 (RLIN)	44469

9 (RLIN)	44534

9 (RLIN)	44535

9 (RLIN)	44536

9 (RLIN)	44499

9 (RLIN)	44537

9 (RLIN)	44538

9 (RLIN)	44539

9 (RLIN)	44540

9 (RLIN)	44541

9 (RLIN)	44542

9 (RLIN)	44543

9 (RLIN)	44544

9 (RLIN)	44545

9 (RLIN)	44546

9 (RLIN)	44547

9 (RLIN)	44548

9 (RLIN)	44549

9 (RLIN)	22887

9 (RLIN)	44550

9 (RLIN)	44414

9 (RLIN)	44551

9 (RLIN)	44430

9 (RLIN)	44552

9 (RLIN)	44553

9 (RLIN)	44554

9 (RLIN)	44555

9 (RLIN)	44556

9 (RLIN)	44557

9 (RLIN)	44558

9 (RLIN)	44559

9 (RLIN)	44560

9 (RLIN)	44561

9 (RLIN)	44562

9 (RLIN)	44563

9 (RLIN)	44564

9 (RLIN)	44565

9 (RLIN)	44566

9 (RLIN)	44567

9 (RLIN)	44568

9 (RLIN)	44569

9 (RLIN)	44570

9 (RLIN)	14627

9 (RLIN)	44571

9 (RLIN)	44445

9 (RLIN)	44572

9 (RLIN)	44573

9 (RLIN)	44574

9 (RLIN)	44575
710 ## - ADDED ENTRY--CORPORATE NAME
9 (RLIN)	44576
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme	ddc
Koha item type	RESEARCH ARTICLES

Holdings
Withdrawn status	Lost status	Source of classification or shelving scheme	Damaged status	Not for loan	Collection	Home library	Current library	Shelving location	Date acquired	Total checkouts	Barcode	Date last seen	Price effective from	Koha item type
						MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO	MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO		10/10/2022		RA0295	10/10/2022	10/10/2022	RESEARCH ARTICLES